Cancer breathalyzer: Researchers developing breath test for possible diagnosis of lung and breast cancers

June 6, 2012 By John Toon and Abby Vogel Robinson
Emory University researcher Dana Allen blows into a device that traps specific compounds found in breath. The compounds are then examined to confirm the presence or absence of cancer. Credit: Gary Meek

(Medical Xpress) -- A breath test designed to detect established lung cancer in humans showed promising results in a study conducted by researchers at the Georgia Institute of Technology and the Winship Cancer Institute of Emory University. The researchers presented their results June 2 at the annual American Society of Clinical Oncology (ASCO) meeting in Chicago.

The Georgia Tech team, led by Charlene W. , Ph.D., and the Winship researchers, led by Geetha D. Vallabhaneni, M.D., found 75 unique breath (BVOCs) that differed between patients with non-small cell (NSCLC) and subjects without the disease.  The study enrolled 25 newly diagnosed female patients with NSCLC and 25 females without the cancer.

The breath compounds of lung cancer patients were also compared with the BVOCs in patients with , a second aim of the study. To do this, Bayer teamed with Winship researcher Sheryl G.A. Gabram, M.D. The researchers recently conducted a clinical study analyzing more than 300 BVOCs in breath samples of 20 healthy women over the age of 40 and 20 women recently diagnosed with stage II-IV breast cancer and who had not yet received treatment. The results showed that the breath analysis was able to determine whether the sample came from a cancer patient or healthy subject 78 percent of the time.

The breath sampler and analytical method used for both studies were developed by Bayer, a principal research scientist at the Georgia Tech Research Institute. The research was funded by a Jim and Sarah Kennedy pilot grant.

As a patient breathes into the device, chemical compounds are trapped and examined by a sensor. The researchers’ sensing methodology combines gas chromatography – a technique for separating complex compounds – with mass spectrometry, which identifies the chemical makeup of a substance. Specific patterns in the compounds are then found and used to determine whether or not the disease is present.

Early diagnosis of lung cancer, the nation’s leading cancer killer, has long been a challenge. A simple and inexpensive to detect NSCLC early would make a big impact on early diagnosis, said Vallabhaneni. When diagnosed at Stage I, the earliest stage, NSCLC is curable in more than 70 percent of cases. In contrast, when diagnosed at Stage 3, NSCLC has a cure rate of less than 25 percent.

Bayer and Vallabhaneni caution that these promising results should be tested in larger studies before the test can be used in routine settings. Next steps include an analysis of the genetic signatures of the 75 differing BVOCs to determine whether the signature varies based on the stage of the disease.

Because it can offer immediate results right in a physician’s office, Bayer expects the device may also help improve early breast cancer detection among those who do not have the resources for a mammogram, more easily conduct interval testing for those with a genetically high risk for breast cancer, and facilitate recurrence testing after breast treatment.

Explore further: Sniffer dogs can be used to detect lung cancer

Related Stories

Sniffer dogs can be used to detect lung cancer

August 18, 2011
Sniffer dogs could be used for the early detection of lung cancer, according to new research published in the European Respiratory Journal.

Cancer on the breath? The nose knows

May 16, 2011
A breath test for "sniffing out" cancer in a person's breath is a step closer to reality, according to a study recently published in the British Journal of Cancer. The study results show that the device developed by Prof. ...

Researchers find malignancy-risk gene signature for early-stage non-small cell lung cancer

January 6, 2012
A malignancy-risk gene signature developed for breast cancer has been found to have predictive and prognostic value for patients with early stage non-small cell lung cancer. The advancement was made by researchers at Moffitt ...

Recommended for you

Researchers discover how enzyme 'shape-shifts' in drug-resistant leukemia

September 26, 2017
St. Jude Children's Research Hospital structural biologists have deciphered how the structure of the enzyme called Abl regulates its activity, enabling the enzyme to switch itself on and off. Understanding Abl's regulation ...

Researchers identify gene variants linked to a high-risk children's cancer

September 25, 2017
Pediatric researchers investigating the childhood cancer neuroblastoma have identified common gene variants that raise the risk of an aggressive form of that disease. The discovery may assist doctors in better diagnosing ...

Prostaglandin E1 inhibits leukemia stem cells

September 25, 2017
Two drugs, already approved for safe use in people, may be able to improve therapy for chronic myeloid leukemia (CML), a blood cancer that affects myeloid cells, according to results from a University of Iowa study in mice.

Cancer vaccines need to target T cells that can persist in the long fight against cancer

September 25, 2017
Cancer vaccines may need to better target T cells that can hold up to the long fight against cancer, scientists report.

MRI contrast agent locates and distinguishes aggressive from slow-growing breast cancer

September 25, 2017
A new magnetic resonance imaging (MRI) contrast agent being tested by researchers at Case Western Reserve University not only pinpoints breast cancers at early stages but differentiates between aggressive and slow-growing ...

Lung cancer treatment could be having negative health effect on hearts

September 25, 2017
Radiotherapy treatment for lung cancer could have a negative effect on the health of your heart new research has found.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.